Journal · Cardiovascular pharmacology · Updated 21 November 2026
Cardiovascular Drugs and Therapy
Read Cardiovascular Drugs and Therapy articles on DeepDyve. No university library needed.
Cardiovascular Drugs and Therapy has published research on treating heart and blood vessel disease since 1987, from the molecular mechanisms behind heart injury to drug therapy and outcomes after cardiac procedures. Springer Nature publishes it. A DeepDyve subscription lets you read it in full, alongside millions of articles from other journals licensed from publishers including Springer Nature.
Then $59 a month or $499 a year. A credit card is required; cancel during the trial and you won’t be charged. You read articles online; PDFs are sold separately.
Personal plans aren’t for business use. Reading for work? See Enterprise.
Cardiovascular Drugs and Therapy at a glance
- Full title
- Cardiovascular Drugs and Therapy
- Abbreviation (NLM)
- Cardiovasc Drugs Ther
- Publisher
- Springer Nature
- Print ISSN
- 0920-3206
- Online ISSN (eISSN)
- 1573-7241
- First published
- 1987
- Subjects
- Cardiology, Drug Therapy, Vascular Diseases
- Access model
- Hybrid (13% free to read in 2026)
Ways to access Cardiovascular Drugs and Therapy
13% of the articles Cardiovascular Drugs and Therapy published from January 1 to November 18, 2026 are open access and free to read. For the rest, look for the authors’ manuscript, check a library, or read them on DeepDyve.
- Open access articles. 13% of Cardiovascular Drugs and Therapy articles published from January 1 to November 18, 2026 carry a Creative Commons license, per Crossref, and are free to read. They’re marked “Open access” below.
- The authors’ accepted manuscript. For subscription articles, Springer Nature lets authors post their accepted manuscript on their own website as soon as it’s accepted, and in a repository such as PubMed Central 12 months after publication.
- Ask the authors. Authors can also share a free, read-only link to their published article through Springer Nature’s SharedIt, so it’s worth asking the authors directly.
- NIH-funded research. For papers accepted on or after July 1, 2025, the US National Institutes of Health requires the accepted manuscript in PubMed Central, free with no embargo from the official publication date.
- A library. Your university, hospital or public library may subscribe to Cardiovascular Drugs and Therapy. Check its journal list and whether it offers remote access.
- DeepDyve. Read Cardiovascular Drugs and Therapy articles online for $59 a month or $499 a year after a free first month. Articles marked LitStream below are in DeepDyve’s LitStream collection, which a subscription lets you read online. PDFs are sold separately, and availability varies by article.
Sources: Springer Nature self-archiving policy; NIH Public Access Policy; open access share from Crossref license data.
Impact factor and metrics
Cardiovascular Drugs and Therapy’s 2025 Journal Impact Factor is 3.5, and its 5-year Impact Factor is 3.7.
3.5
Journal Impact Factor (2025)
3.7
5-year Impact Factor (2025)
8 days
Median time to first decision
Source: journal metrics on the Cardiovascular Drugs and Therapy homepage (Springer Nature), checked November 21, 2026. Impact Factor from Clarivate Journal Citation Reports.
Recent Cardiovascular Drugs and Therapy research worth reading
Published January to July 2026. Summaries describe what the authors report.
-
The Nonlinear Relationship Between Serum Uric Acid and Cardiovascular Disease Risk: Mechanistic Insights and Clinical Implications
Hou and colleagues review epidemiological evidence that the association between serum uric acid and cardiovascular disease may not be linear, including potential U-shaped associations, along with possible biological mechanisms and implications for risk prediction and intervention.
Hou et al. · Cardiovascular Drugs and Therapy, published online March 16, 2026 · DOI 10.1007/s10557-026-07866-7
-
Modulating CGRP Signaling: A Promising Therapeutic Avenue for Attenuating Cardiac Dysfunction in Heart Failure
Ansari and colleagues review the role of calcitonin gene-related peptide (CGRP) in heart failure, covering its protective effects, its depletion in progressive disease stages, therapies targeting CGRP signaling in preclinical and early clinical studies, and cardiovascular safety questions around CGRP antagonists used for migraine.
Ansari et al. · Cardiovascular Drugs and Therapy, published online January 17, 2026 · DOI 10.1007/s10557-025-07830-x
-
Molecular Mechanisms Underlying the Comorbidity of Type 2 Diabetes Mellitus and Coronary Artery Disease: from Insulin Resistance and Inflammation to Endothelial Dysfunction and Therapeutic Implications
Zhong and colleagues review the shared molecular mechanisms behind coexisting type 2 diabetes and coronary artery disease, including insulin resistance, chronic low-grade inflammation and oxidative stress, and discuss treatments that target these shared pathways.
Zhong et al. · Cardiovascular Drugs and Therapy, published online April 25, 2026 · DOI 10.1007/s10557-026-07882-7
-
“In-Hospital Initiation of SGLT-2 Inhibitors in Acute Heart Failure: A Systematic Review and Meta-Analysis of Clinical, Decongestion, and Safety Outcomes”
Ahmed and colleagues’ meta-analysis of 18 randomized trials found that in-hospital SGLT-2 inhibitor initiation in acute heart failure reduced heart failure worsening or hospitalization (RR 0.77, 95% CI 0.67–0.88), with no increase detected in acute kidney injury, hypotension or other serious adverse events.
Ahmed et al. · Cardiovascular Drugs and Therapy, published online July 27, 2026 · DOI 10.1007/s10557-026-07920-4
-
Impact of Single Antiplatelet, Dual Antiplatelet, and Anticoagulation Plus Antiplatelet Therapy on Branch Vessel Patency and Bleeding Risk Following Branched Endovascular Aortic Repair
In a single-center retrospective cohort study of 250 patients undergoing branched endovascular aortic repair, Ye and colleagues report better branch patency with dual than single antiplatelet therapy (sHR 0.72) and higher major bleeding with anticoagulation plus antiplatelet therapy (HR 3.10).
Ye et al. · Cardiovascular Drugs and Therapy, published online May 2, 2026 · DOI 10.1007/s10557-026-07886-3
See every Cardiovascular Drugs and Therapy article on DeepDyve
Related journals
Questions about Cardiovascular Drugs and Therapy
How can I read Cardiovascular Drugs and Therapy articles without a subscription?
13% of Cardiovascular Drugs and Therapy articles published from January 1 to November 18, 2026 are open access and free to read. For subscription articles, Springer Nature lets authors post their accepted manuscript on their own website as soon as it’s accepted, and in a repository such as PubMed Central 12 months after publication. Your library may also subscribe. DeepDyve lets you read Cardiovascular Drugs and Therapy articles online for $59 a month or $499 a year after a free first month.
What is the abbreviation for Cardiovascular Drugs and Therapy?
Cardiovascular Drugs and Therapy’s NLM (PubMed) abbreviation is Cardiovasc Drugs Ther.
What is the ISSN of Cardiovascular Drugs and Therapy?
The print ISSN is 0920-3206 and the online ISSN is 1573-7241.
What is the impact factor of Cardiovascular Drugs and Therapy?
Cardiovascular Drugs and Therapy’s Journal Impact Factor is 3.5 (2025), and its 5-year Impact Factor is 3.7, according to Springer Nature’s published metrics.
Is Cardiovascular Drugs and Therapy open access?
Cardiovascular Drugs and Therapy is a hybrid journal: most articles are published under the subscription model, and authors can choose to publish open access. From January 1 to November 18, 2026, 21 of 158 Cardiovascular Drugs and Therapy articles (13%) carry a Creative Commons license, per Crossref.
Cardiovascular Drugs and Therapy articles on DeepDyve are licensed from Springer Nature. Journal facts as of 21 November 2026.
Start reading Cardiovascular Drugs and Therapy today
One month free, then less than $2 a day. Cardiovascular Drugs and Therapy, plus millions of articles from thousands of journals.





